CorMedix Corp (CRMD): Wutah pendapatan kuartal marang kuartal

Logo korporat perusahaan CorMedix (CRMD)

CorMedix Inc. has achieved liquidity standards driven by operational cash flow from the sale of protective solutions. The quarterly sales trend captures this momentum, where -47.90 determines the latest valuation metric. Growth is supported by the launch of DefenCath for dialysis centers and insurance coverage. The business's uniqueness is validated by the first FDA approval of an antimicrobial catheter lock.

CRMD Wutah dodolan kuartal marang kuartal CorMedix Corp (04.07.2022 - 20.11.2026)

CRMD (CorMedix Inc): rincian analitis lan laporan miturut indikator

- rega saham lan target rega konsensus:
- indikator dhuwit lan ilining kas:
Analisis dhasar perusahaan:CRMD - CorMedix Inc.
Produk sing diprodhuksi CorMedix

When assessing financial stability, it is critical for investors to track revenue growth rates, calculated as the percentage change in sales volume of the current quarter compared to the same period last year, to identify scaling trends. The quarterly sales growth dynamics of CorMedix Inc. (CRMD) reflect the commercial expansion of the drug in the absence of competitors, confirming the company's strong pricing power and the potential for long-term margin expansion.